CLINICAL TRIAL

Treatment for Transplantation, Liver

Waitlist Available · 18+ · All Sexes · Boston, MA

This study is evaluating whether there are differences in immune senescence between liver transplant recipients who are tolerant to their transplants and those who are not.

See full description

About the trial for Transplantation, Liver

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
People aged 18 to 50 years old who have been post-transplant for more than 6 years, or people aged 50 years or older who have been post-transplant for more than 3 years, are at a higher risk for developing skin cancer. show original
Portal inflammation and interface activity is preferably absent, but minimal to focal mild portal mononuclear inflammation may be present. Interface necro-inflammatory activity is absent or equivocal/minimal and, if present, involves a minority of portal tracts and not generally associated with fibrosis
The text discusses how damage to the lymphocytic bile duct, ductopenia, and biliary epithelial senescence changes are absent in patients unless an alternative, non-immunological explanation is found. show original
The fibrosis (if present) should be mild overall, and the bridging between the portal veins should not be more than rare show original
Liver function tests (Direct bilirubin, alanine aminotransferase (ALT)), less than twice the upper limit of normal (ULN). ULN values for liver function tests will be defined by ranges from Harrison's Principles of Internal Medicine, 18th edition
in the study People who have had a liver transplant from either a deceased or living donor are eligible for this study show original
has to take one drug The recipient of a single organ transplant only has to take one drug, which is designed to prevent rejection of the organ. show original
, may be used as continued therapy in patients who have responded to induction therapy Mycophenolate mofetil (MMF) or mycophenolic acid (MPA) at a low dose (≤1500 mg daily or ≤1080 mg daily, respectively) may be used as continued therapy in patients who have responded to induction therapy show original
Findings for obliterative or foam cell arteriopathy are negative
There was no evidence of perivenular inflammation on histologic examination. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: From initiation of immunosuppression withdrawal through 52 weeks after stopping all immunosuppression
Screening: ~3 weeks
Treatment: Varies
Reporting: From initiation of immunosuppression withdrawal through 52 weeks after stopping all immunosuppression
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: From initiation of immunosuppression withdrawal through 52 weeks after stopping all immunosuppression.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 17 secondary outcomes in patients with Transplantation, Liver. Measurement will happen over the course of 3 years after completing immunosuppression withdrawal.

The Incidence of Acute Rejection, Steroid Resistant Rejection, and Chronic Rejection
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
Correlative Value of Recipient Age With Regard to Operational Tolerance
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
Predictive Value of Recipient Age With Regard to Operational Tolerance
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
The Progression of Graft Fibrosis in Tolerant Versus Non- Tolerant Patients
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
The Severity of Acute Rejection, Steroid Resistant Rejection, and Chronic Rejection
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
Proportion of Participants Who Develop Donor-Specific AlloAbs (DSA) or de Novo Anti-human Leukocyte Antigen Human Leukocyte Antigen (HLA) Antibodies
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
3 YEARS AFTER COMPLETING IMMUNOSUPPRESSION WITHDRAWAL
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is transplantation, liver?

Transplantation liver is a surgically transplanted organ and consists of an entire liver. In this respect, it differs from whole organ transplantation. Transplanted organs are not a tissue bank, but are the result of a medical procedure involving transplantation techniques and the anatomy of the recipient. Transplantation, liver can be done with a patient's own cells from the transplant's own tissue. The recipient must be selected with the utmost care. Transplantation, liver therapy is still in its infra-stages.

Anonymous Patient Answer

What are the signs of transplantation, liver?

Early signs of transplant-driven liver disease in patients undergoing intestinal transplantation are low platelet counts and the emergence of autoimmune phenomena. A high serum alanine aminotransferase (ALAT) level is also indicative of transplant-driven liver disease. Liver biopsy is sometimes required in patients with early signs of transplant-driven liver disease to distinguish alcoholic liver disease as a cause of liver dysfunction from a transplant-driven cause.

Anonymous Patient Answer

What causes transplantation, liver?

Every case of liver transplantation should be explained in detail to the patient. In terms of diagnosis, there has been tremendous improvement in accuracy with more accurate and sensitive tests in liver transplants in recent years. All patients should be informed on diagnosis, risk factors and options after a liver transplant.

Anonymous Patient Answer

Can transplantation, liver be cured?

Liver transplantation can be a powerful therapeutic option for selected patients, especially if the condition persists for a prolonged period and has an unfavorable prognosis.

Anonymous Patient Answer

What are common treatments for transplantation, liver?

This is an overview of the treatment options that are utilized in managing the health care of patients with liver diseases. This summary will help inform physicians on the various treatments for patients with hepatic disorders, the various types of medication, and the various treatment approaches for transplantation or liver surgery.

Anonymous Patient Answer

How many people get transplantation, liver a year in the United States?

At least 47,000 liver transplants were performed in the United States annually between 1989 and 2003. The number of liver transplants performed annually declined thereafter.

Anonymous Patient Answer

Does treatment improve quality of life for those with transplantation, liver?

After treatment, a change in HRQL and HRQoL over time was evident. The HRQL and QoL changes were larger than expected, perhaps reflecting the benefits from treatment but perhaps also the natural course of the disease. Further research is urgently required.

Anonymous Patient Answer

How serious can transplantation, liver be?

We concluded that the graft survival and the post-transplantation complication rates are similar to reported rates in the literature. Furthermore, the patient, in terms of survivorship and survival following liver transplantation, are similar to patients with other abdominal malignancies. The major risk is that of liver failure. We do not therefore feel that the transplantation should be withheld from the patient, nor that the patient would benefit from a liver graft.

Anonymous Patient Answer

Does transplantation, liver run in families?

Although the current literature in this paper does not support liver transplantation, it still is important to consider transplantation as an alternative to other treatment options, especially when there is concern for graft dysfunction.

Anonymous Patient Answer

What is the average age someone gets transplantation, liver?

The average patient who does get a liver transplantation is 62 years old. This is lower than all other types of transplantation. Liver transplantation shows a steady increase with age.

Anonymous Patient Answer

Have there been any new discoveries for treating transplantation, liver?

This review found that further research is needed to define the mechanisms of T-cell regulation. It revealed the importance of research on the impact of the human microbiome on transplantation liver function. Further, it highlights the importance of further research into the mechanisms of immune cell development and the way that these newly established T cells acquire their immunogenicity.

Anonymous Patient Answer

What does treatment usually treat?

In one-third of patients, the reason for their immunosuppressive treatment had the possibility of being incorrect. In the future, we need to increase the competence of treating doctors in order to obtain better outcomes. Furthermore, it might be possible to provide an alternative to conventional immunosuppressive therapy in order to minimize the risk of its side effects.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Transplantation, Liver by sharing your contact details with the study coordinator.